candesartan cilexetil has been researched along with Kidney Diseases in 16 studies
candesartan cilexetil: a prodrug which is metabolized to an active form candesartan to exert its biological effects
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the role of angiotensin II (Ang II) in hypertension-induced tissue injury, we gave TCV-116 (1 mg/kg per day PO), a nonpeptide Ang II type I receptor antagonist, or enalapril (10 mg/kg per day PO) to deoxycorticosterone acetate (DOCA)-salt hypertensive rats for 3 weeks and examined the effects on tissue mRNA levels for transforming growth factor-beta 1 (TGF-beta 1) and extracellular matrix components." | 3.69 | Role of angiotensin II in renal injury of deoxycorticosterone acetate-salt hypertensive rats. ( Chatani, F; Hamaguchi, A; Inada, Y; Ishimura, Y; Kim, S; Miura, K; Ohta, K; Omura, T; Wada, T; Yukimura, T, 1994) |
| "Candesartan is an angiotensin II subtype 1 (AT1) receptor antagonist that is administered orally as candesartan cilexetil which is converted in the active compound." | 2.69 | Pharmacokinetics and pharmacodynamics of candesartan cilexetil in patients with normal to severely impaired renal function. ( Buter, H; de Jong, PE; de Zeeuw, D; Navis, GY; Woittiez, AJ, 1999) |
| "Candesartan cilexetil is a potent and long-acting blocker that, when given once a day to patients, provides effective 24 hr blood pressure control." | 2.41 | [Angiotensin II receptor antagonists: candesartan cilexetil]. ( Furukawa, Y; Inada, Y; Kubo, K; Naka, T; Nishikawa, K, 2000) |
| " No relevant pharmacokinetic drug-food or drug-drug interactions are known." | 2.41 | Clinical pharmacokinetics of candesartan. ( Gleiter, CH; Mörike, KE, 2002) |
| " RI was compared to the ARB, candesartan (3 mg/kg/day PO), and to the ACEI, enalapril (60 mg/kg/day PO) in a 4-week dosing paradigm." | 1.35 | A nonpeptide, piperidine renin inhibitor provides renal and cardiac protection in double-transgenic mice expressing human renin and angiotensinogen genes. ( Carlson, T; Kowala, MC; Leadley, R; Major, TC; Okerberg, C; Olszewski, B; Ostroski, R; Rosebury, W; Schroeder, R, 2008) |
| "Candesartan cilexetil was found to have a good safety profile and to be well tolerated by patients with hepatic or renal impairment." | 1.30 | Pharmacokinetics of candesartan cilexetil in patients with renal or hepatic impairment. ( de Zeeuw, D; Kirch, W; Remuzzi, G, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (37.50) | 18.2507 |
| 2000's | 8 (50.00) | 29.6817 |
| 2010's | 1 (6.25) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Ghafil, FA | 1 |
| Kadhim, SAA | 1 |
| Majeed, S | 1 |
| Qassam, H | 1 |
| Hadi, NR | 1 |
| Major, TC | 1 |
| Olszewski, B | 1 |
| Rosebury, W | 1 |
| Okerberg, C | 1 |
| Carlson, T | 1 |
| Ostroski, R | 1 |
| Schroeder, R | 1 |
| Kowala, MC | 1 |
| Leadley, R | 1 |
| Azegami, T | 1 |
| Sasamura, H | 1 |
| Hayashi, K | 2 |
| Itoh, H | 1 |
| Homma, K | 1 |
| Kanda, T | 1 |
| Yoshioka, K | 1 |
| Takamatsu, I | 1 |
| Tatematsu, S | 1 |
| Kumagai, H | 1 |
| Wakino, S | 1 |
| Saruta, T | 1 |
| Meier, CM | 1 |
| Simonetti, GD | 1 |
| Ghiglia, S | 1 |
| Fossali, E | 1 |
| Salice, P | 1 |
| Limoni, C | 1 |
| Bianchetti, MG | 1 |
| Tamura, Y | 1 |
| Kosuga, M | 1 |
| Yamashita, M | 1 |
| Tomioka, S | 1 |
| Sasaki, M | 1 |
| Hikita, T | 1 |
| Nakajima, H | 1 |
| Kojima, K | 1 |
| Uchida, S | 1 |
| Okamura, M | 1 |
| Konishi, Y | 1 |
| Nishimura, M | 1 |
| Umetani, N | 1 |
| Iwai, J | 1 |
| Negoro, N | 1 |
| Inoue, T | 1 |
| Takeda, T | 1 |
| Kanayama, Y | 1 |
| Kim, S | 2 |
| Ohta, K | 1 |
| Hamaguchi, A | 1 |
| Omura, T | 1 |
| Yukimura, T | 1 |
| Miura, K | 1 |
| Inada, Y | 3 |
| Wada, T | 1 |
| Ishimura, Y | 2 |
| Chatani, F | 1 |
| de Zeeuw, D | 3 |
| Remuzzi, G | 1 |
| Kirch, W | 1 |
| Buter, H | 2 |
| Navis, G | 1 |
| de Jong, PE | 2 |
| Navis, GY | 1 |
| Woittiez, AJ | 1 |
| Naka, T | 2 |
| Kubo, K | 1 |
| Nishikawa, K | 1 |
| Furukawa, Y | 1 |
| Gleiter, CH | 1 |
| Mörike, KE | 1 |
| Matsuo, T | 1 |
| Ishikawa, E | 1 |
| Ohta, M | 1 |
| Shibouta, Y | 1 |
| Imura, Y | 1 |
| Sugiyama, Y | 1 |
4 reviews available for candesartan cilexetil and Kidney Diseases
| Article | Year |
|---|---|
[Role of the renin-angiotensin system in cardiovascular and renal diseases].
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Cardiovascular Diseas | 1997 |
[Candesartan cilexetil: pharmacological properties and protective effects against organ damage of a novel nonpeptide angiotensin II-receptor antagonist].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; | 2000 |
[Angiotensin II receptor antagonists: candesartan cilexetil].
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Clinical Trials as To | 2000 |
Clinical pharmacokinetics of candesartan.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biological Availability; | 2002 |
5 trials available for candesartan cilexetil and Kidney Diseases
| Article | Year |
|---|---|
Beneficial action of candesartan cilexetil plus amlodipine or ACE inhibitors in chronic nondiabetic renal disease.
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhi | 2004 |
Palatability of angiotensin II antagonists among nephropathic children.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Bipheny | 2007 |
Renoprotective effects of angiotensin II receptor blocker, candesartan cilexetil, in patients with stage 4-5 chronic kidney disease.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds | 2008 |
Renal hemodynamic effects of candesartan in normal and impaired renal function in humans.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood | 1997 |
Pharmacokinetics and pharmacodynamics of candesartan cilexetil in patients with normal to severely impaired renal function.
Topics: Adult; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Bi | 1999 |
7 other studies available for candesartan cilexetil and Kidney Diseases
| Article | Year |
|---|---|
Nephroprotective effects of Candesartan Cilexetil against Cyclosporine A-induced nephrotoxicity in a rat model.
Topics: Animals; Catalase; Creatinine; Cyclosporine; Immunosuppressive Agents; Interleukin-2; Kidney; Kidney | 2022 |
A nonpeptide, piperidine renin inhibitor provides renal and cardiac protection in double-transgenic mice expressing human renin and angiotensinogen genes.
Topics: Administration, Oral; Albuminuria; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin | 2008 |
Vaccination against the angiotensin type 1 receptor for the prevention of L-NAME-induced nephropathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Enzyme Inhibit | 2012 |
Enhancement of hypertension and renal injury by salt-loading during chronic nitric oxide inhibition. Effects of TCV-116, a novel angiotensin II receptor antagonist.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Arginine; Benzimidazoles; Biphen | 1994 |
Role of angiotensin II in renal injury of deoxycorticosterone acetate-salt hypertensive rats.
Topics: Angiotensin II; Animals; Benzimidazoles; Biphenyl Compounds; Collagen; Desoxycorticosterone; Enalapr | 1994 |
Pharmacokinetics of candesartan cilexetil in patients with renal or hepatic impairment.
Topics: Adolescent; Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; | 1997 |
Renal protective effect of candesartan cilexetil in spontaneously hypercholesterolemic rats.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Be | 2002 |